Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world s
3 hours ago
- #bispecific antibodies
- #multiple myeloma
- #meta-analysis
- BCMA- or GPRC5D-directed CD3 bispecific antibodies show efficacy in treating relapsed/refractory multiple myeloma (RRMM), with a pooled progression-free survival of 8.76 months and an overall response rate of 65.9%.
- Safety analysis reveals significant adverse events, including cytokine release syndrome (67.5%), infections (60.3%), and neutropenia (54.7%), with grade ≥3 events being common.
- The evidence is based on 15 studies involving 1,900 patients, but the certainty is low to very low due to reliance on single-arm trials and retrospective real-world studies, necessitating cautious interpretation.